Qual é o preço para Brii Biosciences Limited (2137)

O preço para Brii Biosciences Limited (2137) é $0.12984512

Qual é a capitalização de mercado para Brii Biosciences Limited (2137)

A capitalização de mercado para Brii Biosciences Limited (2137) é $93.64M

Histórico de Preços de Brii Biosciences Limited (2137)

Founded in Beijing, China, in 2017, Brii Biosciences Limited is a biopharmaceutical firm dedicated to discovering and developing innovative therapies for infectious diseases and central nervous system disorders. Its diverse pipeline features: early-stage (Phase 1) compounds BRII-778 and BRII-732 for treating HIV; a multifaceted approach to Hepatitis B (HBV) including a Phase 2 combination study of BRII-179 and BRII-835, with BRII-179 (a recombinant protein-based immunotherapeutic) also in Phase 1b/2a, and BRII-835 having successfully completed Phase 2 for chronic HBV patients. The company also offers the Amubarvimab/romlusevimab combination as a treatment for COVID-19. Beyond these, Brii Biosciences is advancing BRII-296 for PPD and BRII-297 for various depressive conditions, alongside several agents targeting highly resistant infections: BRII-636, BRII-672, and BRII-693 are designed to combat multi-drug and extensively drug-resistant (MDR/XDR) gram-negative bacteria, while BRII-658 is under development for MDR/XDR tuberculosis and non-tuberculosis mycobacterial infections.

Ano	Desempenho
2026 (TTM)	-4.52%
2025	66.95%
2024	-60.43%
2023	-71.76%
2022	-77.93%
2021	0.00%

Ano

Desempenho

2026 (TTM)

-4.52%

2025

66.95%

2024

-60.43%

2023

-71.76%

2022

-77.93%

2021

0.00%

Empresa	Preço da ação	Variação 1a%	País
Vertex Pharmaceuticals Incorporated VRTX.US	$547.71	38.62%	US
Argenx SE ARGX.US	$1.04K	58.06%	NL
Moderna, Inc. MRNA.US	$145.75	437.43%	US
CSL Limited CSL.AX	$118.70	-15.60%	AU
Lonza Group AG LONN.SW	$770.19	8.98%	CH

Empresa

Preço da ação

Variação 1a%

País